Nephrology
IgAN
Expert Roundtables Podcast: Combination Therapy for IgA Nephropathy
Overview
Combination therapy for IgA nephropathy aims to manage the disease by targeting multiple pathways and is emerging as a new standard of care. Recent research supports tailored combinations of therapies based on individual risk profiles, disease severity, and response to treatment. Listen to today’s podcast for updates on this important topic.
References
Barratt J, Lafayette RA, Floege J. Therapy of IgA nephropathy: time for a paradigm change. Front Med (Lausanne). 2024;11:1461879. doi:10.3389/fmed.2024.1461879
Gentile M, Sanchez-Russo L, Riella LV, et al. Immune abnormalities in IgA nephropathy. Clin Kidney J. 2023;16(7):1059-1070. doi:10.1093/ckj/sfad025
Howie AJ, Lalayiannis AD. Systematic review of the Oxford classification of IgA nephropathy: reproducibility and prognostic value. Kidney360. 2023;4(8):1103-1111. doi:10.34067/KID.0000000000000195
Hunter-Dickson M, Wong MG. The role of endothelin receptor antagonists in IgA nephropathy. Nephrology (Carlton). 2024;29(suppl 2):30-33. doi:10.1111/nep.14364
Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group; Rovin BH, Barratt J, Cook HT, et al. KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV). Kidney Int. 2025;108(suppl 4):S1-S71. doi:10.1016/j.kint.2025.04.004
Miao J, Duriseti P, Radhakrishnan Y, Vaughan L, Fervenza FC, Zand L. Mycophenolate mofetil and steroid for treatment of patients with IgA nephropathy. Kidney Int Rep. 2023;9(1):182-185. doi:10.1016/j.ekir.2023.10.015
Gentile M, Sanchez-Russo L, Riella LV, et al. Immune abnormalities in IgA nephropathy. Clin Kidney J. 2023;16(7):1059-1070. doi:10.1093/ckj/sfad025
Howie AJ, Lalayiannis AD. Systematic review of the Oxford classification of IgA nephropathy: reproducibility and prognostic value. Kidney360. 2023;4(8):1103-1111. doi:10.34067/KID.0000000000000195
Hunter-Dickson M, Wong MG. The role of endothelin receptor antagonists in IgA nephropathy. Nephrology (Carlton). 2024;29(suppl 2):30-33. doi:10.1111/nep.14364
Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group; Rovin BH, Barratt J, Cook HT, et al. KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV). Kidney Int. 2025;108(suppl 4):S1-S71. doi:10.1016/j.kint.2025.04.004
Miao J, Duriseti P, Radhakrishnan Y, Vaughan L, Fervenza FC, Zand L. Mycophenolate mofetil and steroid for treatment of patients with IgA nephropathy. Kidney Int Rep. 2023;9(1):182-185. doi:10.1016/j.ekir.2023.10.015
